We use cookies on our website. Carry on browsing if you’re happy with this or find out more

How our partnerships work

Work with our researchers and technologies

We discover and develop our drugs both independently and in collaboration with pharmaceutical, biotechnology and academic partners. In all our partner collaborations we apply our proprietary technologies, including IntelliSelect™ Transgenic and IntelliSelect™ Screening, to discover, develop and commercialise monoclonal antibodies to difficult and novel drug targets in our therapeutic areas of immuno-oncology, haematology, inflammation and infectious disease.

Strategic partnerships

We have mature partnerships to develop products that serve patients with high unmet medical needs. Our partners access our team of proven drug-discovery and development scientists employing our suite of proprietary technologies including:

our unique antibody discovery and development platforms (for both monospecific and bispecific antibodies) that rapidly generate candidate-quality antibodies with the desired affinity, potency, epitope binding, mechanism of action and biophysical properties; our IntelliSelect™ Screening platform that deeply mines the output from our IntelliSelectTM Transgenic platforms and isolates candidate-quality molecules; our efficient systems to add or remove genes or sequences to pursue challenging drug targets and achieve species cross-reactivity that avoids the need for surrogate molecules in pre-clinical testing.

We are passionate to pursue new collaborations and partnerships that maximise value and impact on patients' lives.

To find out more, please contact: partnering@kymab.com

We discover and develop antibody therapeutics to build a strong portfolio of assets

View our pipeline